CDC Advisors Delay Making a Decision on the Johnson and Johnson Vaccine Pause
Yesterday, vaccine advisers of the CDC put off making any decision about the recommendations for Johnson and Johnson’s Coronavirus vaccine. Members of the Advisory Committee on Immunization Practices cited not enough information about the rare type of blood clot as their reason to delay making changes to their recommendations or even suggesting an extension to the pause of administration of the vaccine. During the meeting, CDC advisors also heard about a possible seventh case and details of one case in a volunteer during the trials of the vaccine.
On Tuesday, the CDC and FDA recommended that the United States pause the use of the Johnson and Johnson vaccine after six cases of a rare but severe and hard-to-treat form of blood clot were reported among women ages 18 to 48 13 days after they received the vaccination. According to Chief Medical Officer for Pharmaceuticals at Johnson and Johnson, of those 6 cases, four were treated with the blood thinner heparin when they first developed symptoms. He also gave details about the cases saying they were experienced by a 45-year-old woman who died; a 38-year-old, an 18-year-old ,a 48-year-old, and a 26-year-old woman who have recovered and a 28-year-old whose status is unknown. The 7th possible case is a 59 year old whose clots may not fit the same profile as the others. The committee will meet sometime in the next 10 days to discuss the situation further.